Vickers A E M, Bentley P, Fisher R L
Novartis Pharmaceuticals Corporation, One Health Plaza, E. Hanover, NJ 07936, United States.
Toxicol In Vitro. 2006 Oct;20(7):1173-82. doi: 10.1016/j.tiv.2006.01.021. Epub 2006 Mar 20.
Inhibition of liver mitochondrial beta-oxidation by pharmaceuticals may lead to safety concerns including mitochondrial dysfunction, lipid accumulation, inflammation and necrosis. In this study, the consequences of mitochondrial beta-oxidation inhibition by pharmaceuticals is investigated in human and rat liver slices. The fatty acid oxidation inhibitors Etomoxir and CPI975, inhibit the rate limiting mitochondrial beta-oxidation enzyme carnitine palmitoyltransferase I, while FOX988 and SDZ51-641, sequester mitochondrial coenzyme A to inhibit carnitine palmitoyltransferase II. Mitochondrial dysfunction was evident by a significant decrease of liver slice ATP levels and mitochondrial injury was verified by ultrastructural changes in morphology, manifested as enlarged mitochondria, C- or O-shaped mitochondria, and granular or crystalline inclusions. Gene expression changes were evident prior to changes in mitochondrial morphology. Time- and concentration dependent changes in mitochondrial genes linked with respiration and mitochondrial fatty acid beta-oxidation were associated with an up-regulation of peroxisome fatty acid oxidation genes, likely as a compensatory mechanism for the inhibition of the mitochondrial pathways. Gene expression changes preceding the decline of liver slice ATP and GSH levels included an up-regulation of stress response and oxidative stress gene expression, as well as genes linked with transcription, transporters, proliferation, cell matrix and signaling. In association with the decline of liver slice ATP and GSH was increased apoptosis and inflammation. Caspase activity, a functional indicator of apoptosis, was significantly increased as well as an up-regulation of genes linked with apoptosis. The increased gene and protein expression of the pro-inflammatory cytokine IL-8, produced by endothelial cells, is likely in response to the manifestation of oxidative stress and GSH depletion; further amplifying the oxidative stress response induced by the fatty acid oxidation inhibitors and triggering an inflammatory response. In summary, human and rat liver slices exhibited similar effects to the inhibitors of mitochondrial beta-oxidation, and the mitochondrial injury is associated with apoptosis and inflammation in the liver slices.
药物对肝脏线粒体β-氧化的抑制可能会引发安全问题,包括线粒体功能障碍、脂质蓄积、炎症和坏死。在本研究中,研究了药物对人及大鼠肝切片中线粒体β-氧化的抑制作用及其后果。脂肪酸氧化抑制剂依托莫西和CPI975抑制限速线粒体β-氧化酶肉碱棕榈酰转移酶I,而FOX988和SDZ51-641螯合线粒体辅酶A以抑制肉碱棕榈酰转移酶II。肝切片ATP水平显著降低表明线粒体功能障碍,线粒体形态的超微结构变化证实了线粒体损伤,表现为线粒体增大、C形或O形线粒体以及颗粒状或结晶状内含物。线粒体形态改变之前基因表达就已发生明显变化。与呼吸和线粒体脂肪酸β-氧化相关的线粒体基因的时间和浓度依赖性变化与过氧化物酶体脂肪酸氧化基因的上调有关,这可能是对线粒体途径抑制的一种补偿机制。在肝切片ATP和谷胱甘肽(GSH)水平下降之前的基因表达变化包括应激反应和氧化应激基因表达的上调,以及与转录、转运体、增殖、细胞基质和信号传导相关的基因表达上调。随着肝切片ATP和GSH水平的下降,细胞凋亡和炎症增加。凋亡的功能指标半胱天冬酶活性显著增加,与凋亡相关的基因也上调。内皮细胞产生的促炎细胞因子白细胞介素-8的基因和蛋白表达增加,可能是对氧化应激和GSH消耗表现的反应;进一步放大了脂肪酸氧化抑制剂诱导的氧化应激反应并引发炎症反应。总之,人及大鼠肝切片对线粒体β-氧化抑制剂表现出相似的效应,且线粒体损伤与肝切片中的细胞凋亡和炎症相关。